Proteinase inhibitors suppress the development of experimental allergic encephalomyelitis.
D015119:Aminocaproic Acid / Q000494:pharmacology; D000818:Animals; D007611:Aprotinin / Q000494:pharmacology; D001565:Benzoates / Q000494:pharmacology; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000201:enzymology*; D006146:Guanidines / Q000494:pharmacology; D007249:Inflammation; D007536:Isomerism; D008297:Male; D010436:Pepstatins / Q000494:pharmacology; D010960:Plasminogen Activators / Q000037:antagonists & inhibitors; D015849:Plasminogen Inactivators; D011480:Protease Inhibitors / Q000494:pharmacology*; D051381:Rats; D014148:Tranexamic Acid / Q000494:pharmacology
D001565:Benzoates; D006146:Guanidines; D010436:Pepstatins; D015849:Plasminogen Inactivators; D011480:Protease Inhibitors; C002238:4-nitrophenyl 4'-guanidinobenzoate; D014148:Tranexamic Acid; D007611:Aprotinin; D010960:Plasminogen Activators; D015119:Aminocaproic Acid